Exhibit #1 510(k) Summary

This 510(k) Summary of 510(k) safety and effectiveness information is being submitted in accordance with requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) Number: K121312

1. Date of Submission: OCT 16, 2012

2. Sponsor
   Weigao Orthopaedic Device Co., Ltd
   No. 26 Xiangjiang Road, Tourist Resorts, Weihai Shandong, 264203, China
   Establishment Registration Number: 3006639944
   Contact Person: Han Wang
   Position: Quality & Technique Manager
   Tel: +86-631-5788966
   Fax: +86-631-5660958
   Email: wanghan@wegortho.com

3. Submission Correspondent
   Ms. Diana Hong & Mr. Lee Fu
   Mid-Link Consulting Co., Ltd
   P.O. Box 237-023, Shanghai, 200237, China
   Tel: +86-21-22815850
   Fax: 240-238-7587
   Email: info@mid-link.net

4. Proposed Device Identification

   Proposed Device Name: Intramedullary Nail System
   Classification: II
   Product Code: HSB
   Regulation Number: 21 CFR 888.3020
   Review Panel: Orthopedic
   Intended Use Statement:
   - Simple, compound first- and second-degree tibial shaft fractures
   - Pseudarthrosis and delayed union

5. Predicate Device Identification

510(k) Number: K053261
Product Name: Orthofix Titanium Nailing System
Submitter: R. Sheridan Consulting. LLC

6. Device Description

The Intramedullary Nail System is a temporary fixation intramedullary nail designed for fracture fixation and stabilization of the tibia. It consists of Intramedullary nail, Locking screw and End cap.

The Intramedullary nail is available in a variety of lengths and diameters to meet assorted anatomical needs. Each of the nails is secured by a series of screws that pass through holes manufactured into the proximal and distal sections of each nail. The Locking screw passes through the holes at the proximal distal sections of intramedullary nail for preventing rotation and axial compression. The End cap which screws into the threaded end of the intramedullary nail provides intraoperative lengths adjustment and prevents tissues growth into nail threads.

All implants of Intramedullary Nail System are manufactured from Ti-6Al-4V alloy that meets the requirements of ASTM F-136. The materials are wildly used in the industry with well known biocompatibility. No new materials are used in the development of this implant.

7. Non-Clinical Test Conclusion

Bench tests were conducted to verify that the proposed device met all design specifications as was Substantially Equivalent (SE) to the predicate device. The test results demonstrated that the proposed device complies with the following standards:

ASTM F1264-03 (Reapproved 2007), Standard Specification and Test Methods for Intramedullary Fixation Devices, including the following items:

- Static bending test
- Static torsion test
- Dynamic bending test

ASTM F 543-07, Standard Specification and Test Methods for Metallic Medical Bone Screws- pullout strength, including the following item:

- Pull out test

8. Substantially Equivalent Conclusion

The proposed device, Intramedullary Nail System, is determined to be Substantially Equivalent (SE) to the predicate device, K053261 Orthofix Titanium Nailing System, in respect of safety and effectiveness.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room –WO66-G609
Silver Spring, MD 20993-0002

Weigao Orthopaedic Device Company, Limited
% Mid-Link Consulting Company, Limited
Ms. Diana Hong
General Manager
PO Box 237-023
Shanghai, China 200237

OCT 24 2012

Re: K121312
Trade/Device Name: Intramedullary Nail System
Regulation Number: 21 CFR 888.3020
Regulation Name: Intramedullary fixation rod
Regulatory Class: Class II
Product Code: HSB
Dated: October 16, 2012
Received: October 22, 2012

Dear Ms. Hong:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

Mark N. Melkerson
Director
Division of Surgical, Orthopedic
and Restorative Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

Section II Indications for Use

510(k) Number: K121312

Device Name: Intramedullary Nail System

Indications for Use:

- Simple, compound first- and second-degree tibial shaft fractures
- Pseudarthrosis and delayed union

☒PRESCRIPTION USE
(Part 21 CFR 801 Subpart D)

☐OVER-THE-COUNTER USE
(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

for

(Division Sign-Off)
Division of Surgical, Orthopedic,
and Restorative Devices

510(k) Number K121312